Decision Diagnostics Corp. (DECN) announced an agreement for a six-month, 8% Promissory Note worth $300,000 with a major investor to support the launch of the GenViro! Swift Kit for Covid-19 testing. Additionally, six existing Promissory Notes with the same investor were extended for an additional four months. The GenViro! Swift Kit is set for release on September 26, 2020, in selected international markets. DECN continues to develop diabetic test strips and expand distribution agreements across various international regions.
Decision Diagnostics Corp (OTC PINK: DECN) plans to launch its International GenViro! Covid-19 Saliva Swift Kit on September 26, 2020, with an initial order of 100,000 kits to meet distributor demand and build inventory. The company aims to fulfill its first shipment of 50,000 kits to India.
The kits will retail at an introductory price of $8.95 and have undergone rigorous testing in Korea. DECN is also seeking FDA authorization for its product while collaborating with international distributors for certifications.
Decision Diagnostics Corp. (OTC PINK:DECN) has made significant progress towards FDA EUA approval for its Covid-19 GenViro! Swift Kit testing methodology. The company is collaborating with a Korea-based partner to finalize saliva and blood rapid testing kits. DECN is now selecting US testing labs and is in discussions with the LA Mayor's Covid-19 Task Force to enhance at-home testing. Preliminary results from Korea indicate high accuracy with less than 5% variance in known-negative tests. The company expects to submit a new FDA application by the end of September.
Decision Diagnostics Corp. (DECN) has issued an 'Open Letter' addressing FDA's new guidelines for at-home rapid testing for COVID-19. CEO Keith Berman critiques the current definitions and regulatory requirements, arguing they may hinder public adoption of these tests. DECN claims its Swift Kits can deliver results in under 10.5 seconds, presenting a viable option against the backdrop of existing lengthy and costly testing methods. The letter emphasizes the urgent need for quicker regulations to facilitate effective testing.